If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

Exscientia Limited (EXAI)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are an artificial intelligence-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Their goal is to change the pharmaceutical industry’s underlying pharmacoeconomic model, what they call "Shifting the Curve", by improving the probability of success, time and cost involved with creating new medicines. Their pipeline demonstrates their ability to rapidly translate scientific concepts into precision-designed therapeutic candidates. They have built a complete end-to-end solution of artificial intelligence, or AI, and experimental technologies for target identification, drug candidate design, translational models and patient selection. Their platform has enabled them to design candidate drug molecules that have progressed into clinical trials as well as to provide patients with potentially more applicable drug therapies through AI guided assessment. Their patient-first AI process is comprised of the following four elements: Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Their AI-design capabilities include a wide range of deep-learning and machine-learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyse patient tissues to prioritise the molecules that are likely to provide the best response for an individual’s specific tumour.
Pharmaceutical Preparations
Employees Founded
208 2012


Address: The Schrödinger Building Oxford Science Park Oxford Ox4 4ge United Kingdom

Telephone: +44 (0) 1865 818941

Web page:

IPO information

First Trade Date 10/1/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 13.1
Shares Revised (MM) 13.85
Expected offer amount (MM) $275.1
Realized offer amount(MM) $304.7

Financial Data (last reporting year)

Market Cap (MM) $2475.9
Revenues (MM) $14.55
Net Income (Loss) (MM) $-54.14


What do you think will happen with the EXAI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Goldman Sachs/ Morgan Stanley/ BofA Securities/ Barclays

Sector: Healthcare

Tweets about $EXAI

Tweets volume:

RT volume:


Google Trends Stats